- SID Score
- 7.6/10
- Fair value
- $493.76
- Generated
- Aug 26, 2026
- Model
- claude-haiku-4-5-20251001
UnitedHealth Group (UNH) is trading at $402.49 with a market capitalization of $305 billion, representing a significant player in the healthcare sector. The stock carries a fair value estimate of $493.76, suggesting 26.6% upside potential, though analyst consensus targets $387.80, implying modest downside risk. With a SID Score of 7.6/10 and mixed factor grades, UNH presents a moderately attractive investment opportunity for healthcare-focused portfolios. The company's valuation appears reasonable at a P/E ratio of 17.4x relative to its earnings growth trajectory.
UnitedHealth Group has demonstrated strong earnings performance, beating estimates consistently in recent quarters with Q3 2026 EPS of $6.38 versus $4.85 expected (31.5% beat) and Q2 2026 EPS of $7.23 versus $6.56 expected (10.2% beat). However, fundamental factor grades reveal concerns: Profitability scores a C-grade while Value receives a D-grade, suggesting the stock may be overvalued relative to its current earnings power and asset base. The company's dividend yield of 0.03% is extremely low, indicating minimal income generation for shareholders. Growth prospects receive a B-grade, reflecting the healthcare sector's resilience but UNH's maturity within the industry.
The stock is trading below its 50-day moving average of $413.66, indicating short-term weakness, though it remains well above the 200-day moving average of $341.75, confirming an intact long-term uptrend. The RSI(14) of 43.6 suggests the stock is neither overbought nor oversold, with room for movement in either direction. The current price sits approximately 18.5% below the 50-day MA, which could present either a buying opportunity if the downtrend reverses or signal continued consolidation. Technical support appears to be forming around the $390-400 level based on recent price action.
Analyst & Insider Sentiment
Analyst consensus rates UNH as a "Buy," though the average price target of $387.80 is approximately 3.6% below the current price, suggesting limited near-term upside according to Wall Street. Insider activity shows mixed signals with recent selling by executives Dennis Stankiewicz (10,058 shares on 8/11) and Patrick Conway (16,497 shares on 8/5), offset by buying by board members McNabb (15,462 shares), Gil (2,617 shares), and Montgomery Rice (7,876 shares) on 7/1. The selling activity from senior management warrants attention, though the buying by board members on the same date suggests confidence in the company's direction. Overall, insider sentiment appears neutral to slightly cautious given the recent executive sales.
UnitedHealth Group faces sector-specific risks including regulatory changes to healthcare policy, reimbursement rate pressures, and potential shifts in the competitive landscape. The company's D-grade in Value metrics and C-grade in Profitability suggest potential valuation concerns if earnings growth fails to materialize or if margins compress. The neutral news sentiment and lack of recent positive catalysts indicate the stock may face headwinds without significant business developments or market catalyst. Additional risks include the divergence between the fair value estimate ($493.76) and analyst consensus ($387.80), indicating significant uncertainty among valuation models.
UnitedHealth Group represents a defensive healthcare holding suitable for growth-oriented investors willing to accept moderate valuation risk for exposure to a market-leading company with consistent earnings execution. The 26.6% upside to fair value provides an attractive risk-reward proposition, particularly if the company continues to beat earnings estimates as it has in recent quarters. However, the conservative analyst consensus, mixed insider activity, and weak fundamental value grades suggest waiting for a more attractive entry point near $385-390 or confirmation of renewed momentum above $415. Investors should monitor earnings quality and margin trends closely, as the sustainability of recent beats will be critical to justifying current valuations and achieving fair value estimates.
